Effects Of Cinepazide Maleate On Inflammatory Factors, Axonal Protein And Neurological Function After Cerebral Infarction In Rats

Objective:Interleukins (ILs) is a group of immune activity factors, mainly produced by mononuclear cells (including lymphocytes and monocytes-macrophages), acting on lymphocytes, macrophages and other cells, with which participate jointly in the immune response and stress response, and regulate inflammation. Clinical and Experimental Researches found that in recent years, ILs were significantly increased after cerebral ischemia, playing a role as neurotoxin, mediating inflammatory response after cerebral ischemia, causing ischemic brain injury. This study is designed to examine the influence of Cinepazide Maleate on cerebral inflammatory response in brain tissue and peripheral blood, cortical axonal protein NF-200 expression and neural function, so as to discuss its neuroprotective effects of CM on ischemic brain injury.Methods:①Ninety-six adult male SD rats were randomly divided into control group, sham group, MCAO/reperfusion group and CM treatment group (n=24). The pathological changes in brain tissue, brain water content, cortex IL-1β, IL-6 and NF-200 expression and neurological function were observed at 2 d, 1 week after ischemia.②Eighty-two patients with acute cerebral infarction were randomly divided into treatment group (n=42) and control group (n=40). Patients in the treatment group were administered with Cinepazide Maleate while these in the control group were given Buflomedil Hydrochloride. The neural function scoring was evaluated and the levels of serum IL-1β, IL-6 were detected before treatment and 2 d, 7 d and 14 d after treatment.Results:①Two days after acute cerebral ischemia, IL-1β, IL-6 expression was significantly inhibited (P<0.01), NF-200 was increased (P<0.01) in CM treated rats, but the brain edema and neurological function score were not be improved (P>0.05). To 1 week after ischemia, IL-1β, IL-6 in ischemia group decreased(P<0.01), the increase of NF-200 were more significant (P<0.01), accompanied by improvement in neurological function (P<0.05), while changes in the treatment group were more significant (P<0.01).②The serum IL-1β, IL-6 levels in treatment group were significantly reduced on 2 d, 7 d after treatment when compared with these of control group (P<0.01) and those before treatment (P<0.01). The neurologic deficits on 7 d, 14 d in both groups were obviously improved (P<0.01) than these before treatment and the total therapeutic effective rate between both groups was not significant (P>0.05). Conclusions :①Cinepazide maleate has certain brain protection against cerebral ischemia/reperfusion injury, its might be associated with the inhibition of IL-1β, IL-6 and the increase of NF-200 in brain tissue.②Cinepazide Maleate is effective as a treatment to patients with acute cerebral infarction and can alleviate the levels of IL-1β, IL-6 in serum of cerebal infarction patients.